Summary

The global autoimmune disease testing market is on a strong growth trajectory, driven by rising awareness of autoimmune conditions and the need for accurate, early diagnosis. The market is projected to grow from US$ 6.94 billion in 2025 to US$ 13.54 billion by 2032, expanding at a notable CAGR of 10.02% during the forecast period. Increased healthcare investments, aging populations, and advancements in diagnostics are key elements contributing to this steady expansion.

Market Insights

Autoimmune diseases affect millions globally, with symptoms often overlapping and diagnosis proving complex. Conditions such as rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease are becoming increasingly common, necessitating improved diagnostic techniques. Healthcare systems are responding by integrating sophisticated testing technologies to support better patient outcomes and streamlined disease management.

Growing adoption of advanced tools like next-generation sequencing, multiplex assays, and AI-powered screening methods is helping healthcare providers improve diagnostic precision. These technologies offer quicker turnaround times, higher throughput, and lower error rates, making them indispensable in clinical settings.

Market Drivers

One of the major growth drivers for the autoimmune disease testing market is the advancement in laboratory automation. Automation reduces reliance on manual testing, enhances efficiency, and improves the accuracy of results, particularly in high-volume testing environments such as central labs and diagnostic centers.

The increasing global prevalence of autoimmune disorders, particularly among aging populations, is also contributing to market growth. Diseases like rheumatoid arthritis are more prevalent among older individuals, aligning with a broader demographic shift toward aging societies worldwide. This is pushing demand for routine and specialized testing to identify and manage these conditions early.

The expansion of diagnostic capabilities in emerging economies is another significant driver. Countries like India are rapidly enhancing their healthcare infrastructure, improving access to testing in both urban and rural regions. Government support in the form of public health initiatives and subsidized diagnostic services is facilitating the spread of autoimmune testing.

Business Opportunities

The growing demand for personalized medicine is opening new avenues in autoimmune diagnostics. With the integration of genomic data and molecular profiling, healthcare professionals can now tailor treatment approaches for individual patients, improving effectiveness and minimizing side effects. This is encouraging the development of companion diagnostic tests that monitor treatment efficacy and disease progression.

Point-of-care testing (POCT) is another area offering high potential. These tests deliver quick and accurate results at the patient's location, allowing for faster treatment decisions. POCT devices are increasingly being used in clinics, hospitals, and even home-care settings due to their convenience and speed.

Regional Analysis

North America continues to dominate the autoimmune disease testing market, largely driven by the United States. The U.S. has a strong healthcare infrastructure, high awareness levels, and growing adoption of point-of-care and automated diagnostic technologies. Government and non-profit initiatives are actively promoting early diagnosis and awareness, supporting robust market expansion.

In Asia Pacific, India is rapidly emerging as a key market due to increasing investments in healthcare and diagnostic infrastructure. The rise in demand for essential tests such as C-reactive protein (CRP), autoantibody panels, and ANA testing reflects the population's growing awareness and access to healthcare services. Government programs aimed at improving rural healthcare are playing a critical role in driving growth in the region.

Key Players

The global autoimmune disease testing market features a mix of established players and emerging innovators. Leading companies have a strong product portfolio, global distribution networks, and significant investments in R&D. Some of the major players include:

• Abbott Laboratories

• Thermo Fisher Scientific

• F. Hoffmann-La Roche Ltd

• Siemens Healthineers

• Bio-Rad Laboratories

• Beckman Coulter (Danaher Corporation)

• Quest Diagnostics

• PerkinElmer, Inc.

• Hologic, Inc.

• Grifols

• bioMérieux

• Werfen (Inova Diagnostics)

• Ortho Clinical Diagnostics

• Trinity Biotech

• EUROIMMUN (A PerkinElmer Company)

These companies are focused on innovation, strategic partnerships, and expansion into high-growth regions to strengthen their market position. Notable developments include Pathkind Diagnostics’ partnership with Sebia to introduce advanced autoimmunity testing in India using Alegra Monotest technology.

Market Restraints

Despite its promising growth, the market faces certain challenges. A major hurdle is the lack of standardization in the quality of immunoassay kits. Variability in test accuracy and reliability across regions can lead to inconsistent diagnostic results, especially in complex conditions like vasculitis. Addressing these inconsistencies is essential to ensure accurate diagnostics and maintain trust in test outcomes.

Emerging Trends and Innovations

Innovations in biomarkers and AI are reshaping autoimmune diagnostics. New biomarkers are enabling differentiation between diseases with similar symptoms, making diagnostics more specific and reliable. AI technologies are being integrated into diagnostic platforms to improve accuracy and support healthcare professionals in decision-making.

Cell-based therapies, such as CAR-T (Chimeric Antigen Receptor) therapy, are gaining traction as a potential one-time treatment for autoimmune disorders. Research initiatives focusing on gender-specific diagnostics are also receiving attention, particularly with autoimmune diseases being more prevalent in women.

Market Segmentation

By Product Type

• Instruments

• Reagents and Consumables

By Disease Type

• Systemic Lupus Erythematosus

• Scleroderma

• Vasculitis

• Inflammatory Bowel Disease

• Rheumatoid Arthritis

• Others

By Test Type

• Inflammatory Markers

• Routine Laboratory Tests

• Anti-Thyroglobulin Antibody

• Antibodies and Immunology Test

• Others

By End User

• Hospitals and Clinics

• Diagnostic Laboratories

• Research Laboratories

• Others

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• The Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Autoimmune Disease Testing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Autoimmune Disease Testing Market Outlook, 2019-2032
3.1. Global Autoimmune Disease Testing Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Instruments
3.1.1.2. Reagents and Consumables
3.2. Global Autoimmune Disease Testing Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Systemic Lupus Erythematosus
3.2.1.2. Scleroderma
3.2.1.3. Vasculitis
3.2.1.4. Inflammatory Bowel Disease
3.2.1.5. Rheumatoid Arthritis
3.2.1.6. Others
3.3. Global Autoimmune Disease Testing Market Outlook, by Test Type, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Inflammatory Markers
3.3.1.2. Routine Laboratory Tests
3.3.1.3. Anti-Thyroglobulin Antibody
3.3.1.4. Antibodies and Immunology Test
3.3.1.5. Others
3.4. Global Autoimmune Disease Testing Market Outlook, by End-user, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. Hospitals and Clinics
3.4.1.2. Diagnostic Laboratories
3.4.1.3. Research Laboratories
3.4.1.4. Others
3.5. Global Autoimmune Disease Testing Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa
4. North America Autoimmune Disease Testing Market Outlook, 2019-2032
4.1. North America Autoimmune Disease Testing Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Instruments
4.1.1.2. Reagents and Consumables
4.2. North America Autoimmune Disease Testing Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Systemic Lupus Erythematosus
4.2.1.2. Scleroderma
4.2.1.3. Vasculitis
4.2.1.4. Inflammatory Bowel Disease
4.2.1.5. Rheumatoid Arthritis
4.2.1.6. Others
4.3. North America Autoimmune Disease Testing Market Outlook, by Test Type, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Inflammatory Markers
4.3.1.2. Routine Laboratory Tests
4.3.1.3. Anti-Thyroglobulin Antibody
4.3.1.4. Antibodies and Immunology Test
4.3.1.5. Others
4.4. North America Autoimmune Disease Testing Market Outlook, by End-user, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. Hospitals and Clinics
4.4.1.2. Diagnostic Laboratories
4.4.1.3. Research Laboratories
4.4.1.4. Others
4.4.2. BPS Analysis/Market Attractiveness Analysis
4.5. North America Autoimmune Disease Testing Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.5.1. Key Highlights
4.5.1.1. U.S. Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
4.5.1.2. U.S. Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
4.5.1.3. U.S. Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
4.5.1.4. U.S. Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
4.5.1.5. Canada Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
4.5.1.6. Canada Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
4.5.1.7. Canada Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
4.5.1.8. Canada Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
4.5.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Autoimmune Disease Testing Market Outlook, 2019-2032
5.1. Europe Autoimmune Disease Testing Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Instruments
5.1.1.2. Reagents and Consumables
5.2. Europe Autoimmune Disease Testing Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Systemic Lupus Erythematosus
5.2.1.2. Scleroderma
5.2.1.3. Vasculitis
5.2.1.4. Inflammatory Bowel Disease
5.2.1.5. Rheumatoid Arthritis
5.2.1.6. Others
5.3. Europe Autoimmune Disease Testing Market Outlook, by Test Type, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Inflammatory Markers
5.3.1.2. Routine Laboratory Tests
5.3.1.3. Anti-Thyroglobulin Antibody
5.3.1.4. Antibodies and Immunology Test
5.3.1.5. Others
5.4. Europe Autoimmune Disease Testing Market Outlook, by End-user, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Hospitals and Clinics
5.4.1.2. Diagnostic Laboratories
5.4.1.3. Research Laboratories
5.4.1.4. Others
5.4.2. BPS Analysis/Market Attractiveness Analysis
5.5. Europe Autoimmune Disease Testing Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.5.1. Key Highlights
5.5.1.1. Germany Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
5.5.1.2. Germany Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.3. Germany Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
5.5.1.4. Germany Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
5.5.1.5. U.K. Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
5.5.1.6. U.K. Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.7. U.K. Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
5.5.1.8. U.K. Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
5.5.1.9. France Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
5.5.1.10. France Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.11. France Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
5.5.1.12. France Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
5.5.1.13. Italy Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
5.5.1.14. Italy Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.15. Italy Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
5.5.1.16. Italy Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
5.5.1.17. Turkey Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
5.5.1.18. Turkey Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.19. Turkey Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
5.5.1.20. Turkey Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
5.5.1.21. Russia Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
5.5.1.22. Russia Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.23. Russia Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
5.5.1.24. Russia Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
5.5.1.25. Rest of Europe Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
5.5.1.26. Rest of Europe Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
5.5.1.27. Rest of Europe Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
5.5.1.28. Rest of Europe Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
5.5.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Autoimmune Disease Testing Market Outlook, 2019-2032
6.1. Asia Pacific Autoimmune Disease Testing Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Instruments
6.1.1.2. Reagents and Consumables
6.2. Asia Pacific Autoimmune Disease Testing Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Systemic Lupus Erythematosus
6.2.1.2. Scleroderma
6.2.1.3. Vasculitis
6.2.1.4. Inflammatory Bowel Disease
6.2.1.5. Rheumatoid Arthritis
6.2.1.6. Others
6.3. Asia Pacific Autoimmune Disease Testing Market Outlook, by Test Type, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Inflammatory Markers
6.3.1.2. Routine Laboratory Tests
6.3.1.3. Anti-Thyroglobulin Antibody
6.3.1.4. Antibodies and Immunology Test
6.3.1.5. Others
6.4. Asia Pacific Autoimmune Disease Testing Market Outlook, by End-user, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. Hospitals and Clinics
6.4.1.2. Diagnostic Laboratories
6.4.1.3. Research Laboratories
6.4.1.4. Others
6.4.2. BPS Analysis/Market Attractiveness Analysis
6.5. Asia Pacific Autoimmune Disease Testing Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.5.1. Key Highlights
6.5.1.1. China Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
6.5.1.2. China Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.3. China Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
6.5.1.4. China Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
6.5.1.5. Japan Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
6.5.1.6. Japan Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.7. Japan Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
6.5.1.8. Japan Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
6.5.1.9. South Korea Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
6.5.1.10. South Korea Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.11. South Korea Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
6.5.1.12. South Korea Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
6.5.1.13. India Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
6.5.1.14. India Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.15. India Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
6.5.1.16. India Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
6.5.1.17. Southeast Asia Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
6.5.1.18. Southeast Asia Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.19. Southeast Asia Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
6.5.1.20. Southeast Asia Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
6.5.1.21. Rest of Asia Pacific Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
6.5.1.22. Rest of Asia Pacific Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
6.5.1.23. Rest of Asia Pacific Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
6.5.1.24. Rest of Asia Pacific Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
6.5.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Autoimmune Disease Testing Market Outlook, 2019-2032
7.1. Latin America Autoimmune Disease Testing Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Instruments
7.1.1.2. Reagents and Consumables
7.2. Latin America Autoimmune Disease Testing Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Systemic Lupus Erythematosus
7.2.1.2. Scleroderma
7.2.1.3. Vasculitis
7.2.1.4. Inflammatory Bowel Disease
7.2.1.5. Rheumatoid Arthritis
7.2.1.6. Others
7.3. Latin America Autoimmune Disease Testing Market Outlook, by Test Type, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Inflammatory Markers
7.3.1.2. Routine Laboratory Tests
7.3.1.3. Anti-Thyroglobulin Antibody
7.3.1.4. Antibodies and Immunology Test
7.3.1.5. Others
7.4. Latin America Autoimmune Disease Testing Market Outlook, by End-user, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Hospitals and Clinics
7.4.1.2. Diagnostic Laboratories
7.4.1.3. Research Laboratories
7.4.1.4. Others
7.4.2. BPS Analysis/Market Attractiveness Analysis
7.5. Latin America Autoimmune Disease Testing Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.5.1. Key Highlights
7.5.1.1. Brazil Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
7.5.1.2. Brazil Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
7.5.1.3. Brazil Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
7.5.1.4. Brazil Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
7.5.1.5. Mexico Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
7.5.1.6. Mexico Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
7.5.1.7. Mexico Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
7.5.1.8. Mexico Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
7.5.1.9. Argentina Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
7.5.1.10. Argentina Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
7.5.1.11. Argentina Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
7.5.1.12. Argentina Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
7.5.1.13. Rest of Latin America Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
7.5.1.14. Rest of Latin America Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
7.5.1.15. Rest of Latin America Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
7.5.1.16. Rest of Latin America Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
7.5.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Autoimmune Disease Testing Market Outlook, 2019-2032
8.1. Middle East & Africa Autoimmune Disease Testing Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Instruments
8.1.1.2. Reagents and Consumables
8.2. Middle East & Africa Autoimmune Disease Testing Market Outlook, by Disease Type, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Systemic Lupus Erythematosus
8.2.1.2. Scleroderma
8.2.1.3. Vasculitis
8.2.1.4. Inflammatory Bowel Disease
8.2.1.5. Rheumatoid Arthritis
8.2.1.6. Others
8.3. Middle East & Africa Autoimmune Disease Testing Market Outlook, by Test Type, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Inflammatory Markers
8.3.1.2. Routine Laboratory Tests
8.3.1.3. Anti-Thyroglobulin Antibody
8.3.1.4. Antibodies and Immunology Test
8.3.1.5. Others
8.4. Middle East & Africa Autoimmune Disease Testing Market Outlook, by End-user, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. Hospitals and Clinics
8.4.1.2. Diagnostic Laboratories
8.4.1.3. Research Laboratories
8.4.1.4. Others
8.4.2. BPS Analysis/Market Attractiveness Analysis
8.5. Middle East & Africa Autoimmune Disease Testing Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.5.1. Key Highlights
8.5.1.1. GCC Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
8.5.1.2. GCC Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.3. GCC Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
8.5.1.4. GCC Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
8.5.1.5. South Africa Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
8.5.1.6. South Africa Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.7. South Africa Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
8.5.1.8. South Africa Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
8.5.1.9. Egypt Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
8.5.1.10. Egypt Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.11. Egypt Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
8.5.1.12. Egypt Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
8.5.1.13. Nigeria Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
8.5.1.14. Nigeria Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.15. Nigeria Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
8.5.1.16. Nigeria Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
8.5.1.17. Rest of Middle East & Africa Autoimmune Disease Testing Market by Product Type, Value (US$ Bn), 2019-2032
8.5.1.18. Rest of Middle East & Africa Autoimmune Disease Testing Market by Disease Type, Value (US$ Bn), 2019-2032
8.5.1.19. Rest of Middle East & Africa Autoimmune Disease Testing Market by Test Type, Value (US$ Bn), 2019-2032
8.5.1.20. Rest of Middle East & Africa Autoimmune Disease Testing Market by End-user, Value (US$ Bn), 2019-2032
8.5.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis, 2025
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. Abbott Laboratories
9.3.1.1. Company Overview
9.3.1.2. Therapy Portfolio
9.3.1.3. Financial Overview
9.3.1.4. Business Strategies and Development
9.3.2. Thermo Fisher Scientific
9.3.2.1. Company Overview
9.3.2.2. Therapy Portfolio
9.3.2.3. Financial Overview
9.3.2.4. Business Strategies and Development
9.3.3. F. Hoffmann-La Roche Ltd
9.3.3.1. Company Overview
9.3.3.2. Therapy Portfolio
9.3.3.3. Financial Overview
9.3.3.4. Business Strategies and Development
9.3.4. Siemens Healthineers
9.3.4.1. Company Overview
9.3.4.2. Therapy Portfolio
9.3.4.3. Financial Overview
9.3.4.4. Business Strategies and Development
9.3.5. Bio-Rad Laboratories
9.3.5.1. Company Overview
9.3.5.2. Therapy Portfolio
9.3.5.3. Financial Overview
9.3.5.4. Business Strategies and Development
9.3.6. Beckman Coulter (Danaher Corporation)
9.3.6.1. Company Overview
9.3.6.2. Therapy Portfolio
9.3.6.3. Financial Overview
9.3.6.4. Business Strategies and Development
9.3.7. Quest Diagnostics
9.3.7.1. Company Overview
9.3.7.2. Therapy Portfolio
9.3.7.3. Financial Overview
9.3.7.4. Business Strategies and Development
9.3.8. PerkinElmer, Inc.
9.3.8.1. Company Overview
9.3.8.2. Therapy Portfolio
9.3.8.3. Financial Overview
9.3.8.4. Business Strategies and Development
9.3.9. Hologic, Inc.
9.3.9.1. Company Overview
9.3.9.2. Therapy Portfolio
9.3.9.3. Financial Overview
9.3.9.4. Business Strategies and Development
9.3.10. Grifols
9.3.10.1. Company Overview
9.3.10.2. Therapy Portfolio
9.3.10.3. Financial Overview
9.3.10.4. Business Strategies and Development
9.3.11. bioMérieux
9.3.11.1. Company Overview
9.3.11.2. Therapy Portfolio
9.3.11.3. Financial Overview
9.3.11.4. Business Strategies and Development
9.3.12. Werfen (Inova Diagnostics)
9.3.12.1. Company Overview
9.3.12.2. Therapy Portfolio
9.3.12.3. Financial Overview
9.3.12.4. Business Strategies and Development
9.3.13. Ortho Clinical Diagnostics
9.3.13.1. Company Overview
9.3.13.2. Therapy Portfolio
9.3.13.3. Financial Overview
9.3.13.4. Business Strategies and Development
9.3.14. Trinity Biotech
9.3.14.1. Company Overview
9.3.14.2. Therapy Portfolio
9.3.14.3. Financial Overview
9.3.14.4. Business Strategies and Development
9.3.15. EUROIMMUN (A PerkinElmer Company)
9.3.15.1. Company Overview
9.3.15.2. Therapy Portfolio
9.3.15.3. Financial Overview
9.3.15.4. Business Strategies and Development
9.3.16. Others
9.3.16.1. Company Overview
9.3.16.2. Therapy Portfolio
9.3.16.3. Financial Overview
9.3.16.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations